Sponsored By
ABOUT THE AWARDS
Join us in celebrating the 11th anniversary of the Global Generics and Biosimilars Awards, a valued recognition of outstanding accomplishments and groundbreaking innovations in the global off-patent pharmaceutical landscape. Held during CPhI Worldwide week in Milan, these prestigious Awards serve as a distinctive platform for industry leaders to convene, engage in insightful discussions about future prospects and challenges, and applaud the exceptional contributions of companies and individuals fostering positive transformations.
Celebrated across 14 distinguished categories, including Biosimilar Initiative of the Year, Leader of the Year, and API Supplier of the Year, we will honor the trailblazers shaping the industry.
Entries for the Global Generics and Biosimilars Awards are open to all at no cost. The thorough judging process will take place throughout the summer, with the announcement of finalists scheduled for September. Witness the unveiling of the winners during the Awards ceremony on Wednesday, 9 October, 2024.
Key details
- Ceremony: Wednesday, 9 October, 2024
- Free to attend!
- Hotel NH Milano Fiera
WHO COULD ENTER
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
FINALISTS
- Aurobindo Pharma
- Eurofarma Laboratórios
- Sandoz
WHO COULD ENTER
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
FINALISTS
- Biogen (Biosimilars Business Unit)
- Boehringer Ingelheim
- Samsung Bioepis
- Sandoz
- Stada
WHO COULD ENTER
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
FINALISTS
- Accord Healthcare
- Adalvo
- Surge Laboratories
- Unipharm
WHO COULD ENTER
This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.
FINALISTS
- Accord Healthcare
- Celltrion
- Canadian Generic Pharmaceutical Association
- Surge Laboratories
- Teva Pharmaceuticals
WHO COULD ENTER
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
FINALISTS
- Accord Healthcare
- Aurobindo Pharma
- Samsung Bioepis
- Sandoz
- Stada
WHO COULD ENTER
Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.
-
Company of the Year — Americas | sponsored by
FINALISTS
- Amneal
- Dr.Reddy's – Americas
- Eurofarma Laboratórios
- Company of the Year — Asia-Pacific
FINALISTS
- Aurobindo Pharma
- Biocon
- Samsung Bioepis
- Surge Laboratories - Nabiqasim Pharma Group
- Company of the Year — EMEA
FINALISTS
- Generis Farmacêutica, S.A.
- Sandoz Region Europe
- Stada
WHO COULD ENTER
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
FINALISTS
- Eurofarma Laboratórios
- Hemofarm Foundation
- Olpha (ex-Olainfarm)
WHO COULD ENTER
Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.
FINALISTS
- Accord Healthcare (partnership with Synthon)
- Adalvo
- Affygility Solutions
- Lambda Therapeutic Research
- Rephine
WHO COULD ENTER
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
FINALISTS
- Paul Tredwell, Executive Vice President, Accord Healthcare EMENA
- Anil Okay, founder and CEO, Adalvo
- V Muralidharan (Murali), CEO, Aurobindo Pharma Europe
- Judit Serra, Director of Innovation and Technology Development, Centrient
- Richard Saynor, CEO, Sandoz
- Peter Goldschmidt, CEO, Stada
WHO COULD ENTER
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
FINALISTS
- Abyolo
- Biocon
- Samsung Bioepis
- Sandoz
- Stada
HEADLINE SPONSOR
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.
The company that started less than four decades ago as a single unit manufacturing Semi-Synthetic Penicillin (SSP) has now grown into a $ 3.5 billion global business with presence in over 150 countries and in all major therapeutic segments; API, FDF, Biocatalysts , Vaccines, Peptides and Biologicals.
With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs in India.
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org
